Skip to main content
  • Register
  • Help
  • Contact us

Cue Biopharma Inc (CUE) Com USD0.001

Sell:$10.45 Buy:$12.24 Change: $0.36 (3.20%)
Market closed |  Prices as at close on 6 May 2021 | Switch to live prices |
Sell:$10.45
Buy:$12.24
Change: $0.36 (3.20%)
Market closed |  Prices as at close on 6 May 2021 | Switch to live prices |
Sell:$10.45
Buy:$12.24
Change: $0.36 (3.20%)
Market closed |  Prices as at close on 6 May 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Cue Biopharma Inc is a development-stage immunotherapy company. The Company is focused at developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease. Its Immuno-Oncology pipeline includes CUE-100 Framework, and CUE-200 Framework; and autoimmune pipeline includes MHC Class I Program, and MHC Class II Program. The CUE-100 Framework restricts the activity of T cell populations. The CUE-200 Framework enables potent, long-lived anti-tumor T cell responses. The Autoimmune disease therapy protects the healthy cells from immune attack.

Contact details

Address:
21 Erie St
CAMBRIDGE
02139-4260
United States
Telephone:
+1 (617) 9492680
Website:
https://www.cuebiopharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CUE
ISIN:
US22978P1066
Market cap:
$343.45 million
Shares in issue:
30.50 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Frank Morich
    Independent Chairman of the Board
  • Anish Suri
    President, Chief Scientific Officer
  • Daniel Passeri
    Chief Executive Officer, Director
  • Kerri-Ann Millar
    Chief Financial Officer
  • Colin Sandercock
    Senior Vice President, General Counsel, Secretary
  • Kenneth Pienta
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.